Trial Profile
Randomized phase II study of aprepitant in patients with colorectal cancer receiving FOLFOX, FOLFIRI, or XELOX chemotherapy regimen.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Dexamethasone; Dexamethasone; Serotonin 3 receptor antagonists
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- Acronyms KASCC
- 26 Nov 2011 New trial record